Evidence map›Paper›PMID 34756080›Full record

ArticleMicrobiology spectrum2021

Christi L McElheny, Erin L Fowler, Alina Iovleva, Ryan K Shields, Yohei Doi

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 62 citations in OpenAlex.

  1. ISEmerging microbes & infections · 2026
    Article
  2. Article
  3. JAC-antimicrobial resistance · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. TheMicrobiology spectrum · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christi L McElhenyDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Erin L FowlerDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Alina IovlevaDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Ryan K ShieldsDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9794-5665
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9620-2525
University of Pittsburgh · USFujita Health University · JP

Funding

Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2M
Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP)R21AI135522 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2018 to 2019
$460k
Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRER21AI151363 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2021 to 2022
$431k
Mechanisms of cefiderocol resistanceR21AI151362 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2020 to 2021
$420k
Characterization and suppression of resistance to new CRE agentsR03AI144636 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2019 to 2020
$157k
NIAID NIH HHS R03 AI144636NIAID NIH HHS R21 AI135522NIAID NIH HHS R21 AI151362NIAID NIH HHS R21 AI151363
6 · The paper itself

Abstract

By serially exposing an NDM-producing Klebsiella pneumoniae clinical strain to cefiderocol, we obtained a mutant with cefiderocol MIC of >128 μg/ml. The mutant contained an early stop codon in the iron transporter gene

Indexed as

Amino Acid SequenceAmino Acid SubstitutionAnti-Bacterial Agentsbeta-LactamasesCation Transport ProteinsCefiderocolCephalosporinsCodon, NonsenseDrug Resistance, Multiple, BacterialFrameshift MutationHigh-Throughput Nucleotide SequencingKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsSiderophoresAnti-Bacterial Agentsbeta-lactamase NDM-1beta-LactamasesCation Transport ProteinsCefiderocolCephalosporinsCodon, NonsenseSiderophorescefiderocoliron transportersiderophore

Identifiers

PMID34756080
PMCPMC8579844
OpenAlexW3214569295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.